9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors

Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors

Estimated reading time: < 1 min

Condition: Breast Cancer

Estimated Enrollment: 16

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Completed

Study Results: No Results Available

Outcome Measures: Maximum tolerated dose of sorafenib tosylate,  Disease Response,  Maximum, Minimum and AUC Concentrations of Sorafenib,

Interventions: cisplatin, pemetrexed disodium

Phase:

Study Type: Interventional

Study Design: Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment,

Primary Completion Date: September 2010

Completion Date: November 2010

Last  Posted Date: November 29, 2017

Location: Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States

Website Link: https://ClinicalTrials.gov/show/NCT00703638

Was this article helpful?
Dislike 0